ASCEND PLUS Trial Investigates Semaglutide's Cardiovascular Protection in Type 2 Diabetes Without Prior Events

Type 2 diabetes (T2D) significantly elevates the risk of major adverse cardiovascular events (MACE), including heart attack, stroke, and cardiovascular death. Despite advancements in glycemic control, a substantial residual risk of MACE persists, particularly in patients without a history of such events. Current standard-of-care often focuses on managing existing cardiovascular disease, but there's a critical need for primary prevention strategies in the broader T2D population. Glucagon-like peptide 1 receptor (GLP-1R) agonists like semaglutide have demonstrated cardiovascular benefits in T2D patients with established cardiovascular disease or high risk, but their role in primary prevention for those without prior events warrants further investigation.

The ASCEND PLUS trial is a large-scale, randomized, placebo-controlled study designed to evaluate the cardiovascular safety and efficacy of semaglutide in individuals with type 2 diabetes who have no prior history of heart attack or stroke. Participants will regularly take a tablet called semaglutide (dose not specified in abstract, but implied to be a standard oral dose) or a placebo. The primary endpoint is a composite of major adverse cardiovascular events, including nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death. Secondary endpoints include procedures to unblock or bypass heart arteries and mini-strokes. The trial is sponsored by the University of Aberdeen, with an anticipated completion date of July 2028.

The ASCEND PLUS trial is currently not yet recruiting, with an anticipated start date of August 2025 and completion in July 2028. Therefore, no findings are available at this time. The study aims to determine if regular oral semaglutide can safely reduce the incidence of major adverse cardiovascular events in type 2 diabetes patients who have not previously experienced a heart attack or stroke. Results from this trial are crucial for understanding the primary prevention potential of GLP-1R agonists in this specific patient population.